<DOC>
	<DOCNO>NCT01340027</DOCNO>
	<brief_summary>The purpose study examine well two medicine combination ( solifenacin succinate mirabegron ) work treatment bladder problem 12-week period .</brief_summary>
	<brief_title>A Study Evaluate Efficacy , Safety Tolerability Mirabegron Solifenacin Succinate Alone Combination Treatment Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Urological Manifestations</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Inclusion Criteria Visit 1/Screening : Subject Body Mass Index ( BMI ) 18 35 kg/m^2 total body weight 50 95 kg ; Subject willing able complete micturition diary questionnaire correctly willing able measure his/her vital sign home stipulate time point , use device provide study personnel , adequately record reading ; Subject symptom overactive bladder ( OAB ; urinary frequency , urgency and/or urgency incontinence ) least 3 month . Inclusion Criteria Visit 3/Baseline : Subject experience frequency micturition average ≥ 8 time per 24hour period 3day micturition diary period ( incontinence episode count micturition ) ; Subject must experience least 1 episode urgency ( grade 3 4 ) per 24hour period ( without urgency incontinence ) 3 day micturition diary period . Exclusion Criteria Visit 1/Screening : Subject breastfeeding , pregnant intend become pregnant study . The pregnancy test ( Beta Human Chorionic Gonadotropin serum ) Screening must negative woman childbearing potential ; Female subject childbearing potential use highly effective method birth control study 30 day final study drug administration . Male subject ( unless surgically sterile ) female spouses/partners childbearing potential , use barrier method contraception study 30 day final study drug administration . In addition , female spouses/partners male subject childbearing potential also use highly effective method birth control study 30 day final study drug administration . Highly effective method birth control define , alone combination , result low failure rate ( i.e . le 1 % per year ) use consistently correctly . Subject significant postvoid residual ( PVR ) volume ( &gt; 150 mL ) ; Subject significant stress incontinence mixed stress/urgency incontinence stress predominant factor determine Investigator ( female subject confirm cough provocation test ) ; Subject neurological cause detrusor overactivity ; Subject indwell catheter practice intermittent selfcatheterization ; Subject diabetic neuropathy ; Subject chronic inflammation interstitial cystitis , bladder stone , previous pelvic radiation therapy previous current malignant disease pelvic organ ; Subject previous low urinary tract pelvic floor surgery ( except cystoscopy ) ; Subject intravesical treatment past 12 month e.g. , botulinum toxin , resiniferatoxin , capsaicin ; Subject uncontrolled narrow angle glaucoma , urinary gastric retention , severe ulcerative colitis Crohn 's Disease , toxic megacolon , myasthenia gravis condition make use anticholinergic contraindicate ; Subject clinically significant cardiovascular cerebrovascular disease within 6 month prior Screening , myocardial infarction , uncontrolled angina , significant ventricular arrhythmia , heart failure stroke ; Subject receive current nondrug treatment include electrostimulation therapy ( exception bladder training program pelvic floor exercise start 30 day prior Screening ) ; Subject use medication intend treat OAB prohibit medication . Subject know suspected hypersensitivity solifenacin succinate , mirabegron excipients ; Subject significant neurological disease defect affect bladder function ( e.g. , neurogenic bladder , systemic central neurological disease multiple sclerosis [ MS ] Parkinson 's disease ) ; Subject severe hypertension define sit average systolic blood pressure ≥ 180 mmHg and/or average diastolic blood pressure ≥ 110 mmHg ; Exclusion Criteria Visit 2/Placebo RunIn : Subject evidence urinary tract infection ( UTI ) ( urine culture contain &gt; 100,000 cfu/mL ) . The subject enrol study successful treatment UTI ( confirm laboratory result negative urine culture ) . However , subject must screen initial screen visit &gt; 28 day ; Subject QT interval &gt; 450 m risk QT prolongation ( e.g. , family history long QT syndrome , hypokalaemia ) drug treatment know associated QT prolongation ; Subject clinically significant abnormality 12 lead electrocardiogram ( ECG ) ; Subject serum creatinine &gt; 150 µmol/L , aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2x upper limit normal ( ULN ) , gammaglutamyltransferase ( γGT ) &gt; 3x ULN , total bilirubin &gt; 2x ULN , assess Screening sample ; Exclusion Criteria Visit 3/Baseline : Subject average total daily urine volume &gt; 3000 mL record micturition diary period ; Subject severe hypertension define sit average systolic blood pressure ≥ 180 mmHg and/or average diastolic blood pressure ≥ 110 mmHg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Overactive bladder ( OAB )</keyword>
	<keyword>Frequency</keyword>
	<keyword>Micturition</keyword>
	<keyword>Urgency</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>Urgency incontinence</keyword>
	<keyword>YM178</keyword>
</DOC>